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Armolipid Plus (AP) is a nutraceutical that contains policosanol, fermented rice with red
yeast, berberine, coenzyme Q10, folic acid, and astaxanthin. It has been shown to be effec-
tive in reducing plasma LDL cholesterol (LDLc) levels. In the multicenter randomized trial
NCT01562080, there was large interindividual variability in the plasma LDLc response to
AP supplementation. We hypothesized that the variability in LDLc response to AP supple-
mentation may be linked to LDLR and PCSK9 polymorphisms.
Material and Methods
We sequenced the LDLR 30 and 50 untranslated regions (UTR) and the PCSK9 50 UTR of
102 participants with moderate hypercholesterolemia in trial NCT01562080. In this trial, 50
individuals were treated with AP supplementation and the rest with placebo.
Results
Multiple linear regression analysis, using the response of LDLc levels to AP as the depen-
dent variable, revealed that polymorphisms rs2149041 (c.-3383C>G) in the PCSK9 50 UTR
and rs14158 (c.*52G>A) in the LDLR 30 UTR explained 14.1% and 6.4%, respectively, of
the variability after adjusting for gender, age, and BMI of individuals. Combining polymor-
phisms rs2149041 and rs14158 explained 20.5% of this variability (p < 0.004).
Conclusions
Three polymorphisms in the 30 UTR region of LDLR, c.*52G>A, c.*504G>A, and c.
*773A>G, and two at the 50 UTR region of PCSK9, c.−3383C>G and c.−2063A>G, were
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associated with response to AP. These results could explain the variability observed in the
response to berberine among people with moderate hypercholesterolemia, and they may
be useful in identifying patients who could potentially benefit from supplementation with AP.
Introduction
Hypercholesterolemia is a major risk factor for coronary heart disease. Several studies have
demonstrated that lowering elevated plasma total cholesterol (TC) levels, particularly low-den-
sity lipoprotein cholesterol (LDLc), is beneficial for patients with borderline to mildly elevated
TC and LDLc levels [1–4].
There is growing interest in using nutraceuticals for hypercholesterolemia management for
two reasons: (1) Patients with metabolic conditions that can be addressed by nutraceuticals
may prefer therapeutic management that does not involve drug treatment. (2) There may be a
high incidence of clinical side effects associated with the drugs used to treat their condition [5].
This is particularly the case for patients with hypercholesterolemia who are taking 3-hydroxy-
3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, also known as statins. Statins
are effective at reducing plasma cholesterol and the risk of cardiovascular disease (CVD).
Although they have proven efficacy, they are associated with a relatively high incidence of clini-
cal side effects, such as myopathy and myalgia [6–8].
The nutraceutical Armolipid Plus (AP) was recently reported to be associated with signifi-
cant improvements in plasma lipids, insulin resistance, and other components of metabolic
syndrome; it was associated with an overall decrease in the risk of CVD in a population with
hyperlipidemia and medium-to-high CVD risk [9–13]. AP contains policosanol, fermented
rice with red yeast, berberine, coenzyme Q10, folic acid, and astaxanthin. It has been shown
that fermented rice with red yeast contains lovastatin, and its hypocholesterolemic effects were
described in a meta-analysis [14]. Policosanols and fermented rice with red yeast have a hypo-
cholesterolemic effect by inhibiting cholesterol through regulation of overexpression of
HMGCoA reductase enzymatic activity [15] and also by decreasing HMG-CoA reductase
activity by activating AMP-kinase [16].
Berberine has a hypocholesterolemic effect distinct from that of the statins [16]. The mecha-
nism involves post-transcriptional upregulation of LDL receptor (LDLR) through mRNA sta-
bilization. Its action is independent of sterol regulatory binding proteins (SREBP), but it is
dependent on extracellular signal–regulated protein kinase (ERK) activation [17]. The mRNA
stabilization mediated by berberine involves the 50 proximal section of the 30 untranslated
region (UTR) of LDLR [17]. Moreover, berberine downregulates proprotein convertase subtili-
sin/kexin type 9 (PCSK9). It was recently reported that berberine also exerts inhibitory effects
on the expression of PCSK9 protein and mRNA in HepG2 cells [18]. In vitro, BBR inhibits
PCSK9 mRNA and protein expression through the SRE andHNF1 promoter sites [19]. It has
been shown that the inhibitory effect of berberine is partially abolished by single mutations in
the SRE or HNF1 binding sites of PCSK9 [19].
A recent study found considerable interindividual variation in the response of plasma LDLc
levels to AP supplementation [13]. This variation may be caused by genetic differences, but the
specific genes involved in the hypocholesterolemic effects of AP are largely unknown. We
hypothesized that the variability in plasma lipid responses to AP supplementation could be
linked to interactions of berberine with the PCSK9 and LDLR promoters, as well as with LDLR
30 UTR variants, because such interactions could potentially alter the transcriptional activity
and mRNA stabilization of both genes. The aim of the present study was to determine if genetic
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variations in PCSK9 and LDLR were associated with differences in individual hypocholesterole-
mic responses to the nutraceutical AP.
Materials and Methods
Study subjects
The subjects of the present study were participants in a randomized, double-blind, parallel,
controlled, and multicenter trial (ClinicalTrials.gov number NCT01562080) conducted in
hypercholesterolemic subjects with low CVD risk. The participants received one tablet/day of
AP (n = 51, mean age ± SD 49.91 ± 11.61 years) or placebo (microcrystalline cellulose; n = 51,
mean age 52.37 ± 11.15 years) for 12 weeks with dietary recommendations. The AP tablets con-
tained berberine (500 mg), red yeast rice extract (200 mg), policosanol (10 mg), folic acid (0.2
mg), coenzyme Q10 (2 mg), and asthaxantine (0.5 mg).
The subjects’ characteristics and clinical trial details were described previously [13]. Briefly,
the study included a total of 102 participants with low CVD risk and mild-to-moderately ele-
vated LDLc (130–189 mg/dL) without hypolipemic therapy. Among the exclusion criteria were
any concomitant chronic disease, triglycerides (TG)> 3.97 mmol/L, pregnancy or lactation,
and history of CVD. At 12 weeks, compared to placebo, AP reduced LDLc by 26.9%, apolipo-
protein (Apo) B-100 by 26.6%, total cholesterol/HDLc ratio by 25.5%, and ApoB/ApoA1 ratio
by 28.6%, while ApoA1 was increased by 2.5% (p< 0.05) [13].
All subjects provided written informed consent to a protocol approved by the ethical review
boards of Hospital Virgen del Rocío (Sevilla), Hospital San Jorge (Huesca), Hospital San Pedro
(Logroño), Hospital Gregorio Marañón (Madrid), Hospital la Fe (Valencia) and Hospital San
Joan (Reus). Protocols were in accordance with the Helsinki Declaration and good clinical
practice guidelines of the International Conference of Harmonization (ICH GCP), and the ran-
domized trial was conducted in accordance with the extended CONSORT 2010 guidelines.
Genetic analysis
Genomic DNA was extracted from peripheral blood leukocytes with the DNA Extraction G
BACC3 Nucleon kit (General Electric). Using TRANSFACT1, MAPPER, and JASPAR, single
nucleotide variants (SNVs) in potential binding sites for transcription factors in the LDLR and
PCSK9 50 UTR were selected according to their likelihood of having a minor allele frequency of
>5% according to European data from the 1000 Genomes Project. SNVs previously analyzed
by our group were also included [20]. The SNVs selected in these regions were: rs2149041,
rs2479406, rs17111503, rs2479408, and rs2479409 in PCSK9 and rs17242346, rs17248720, and
rs17249120 in LDLR. To genotype these SNVs, two fragments (from c.−2126 to c.−1287 and
from c.−883 to c.−637) and three fragments (from c.−3472 to c.−2752, from c.−2210 to c.
−1937, and from c.−1394 to c.−738) were amplified from LDLR and PCSK9 50 UTR, respec-
tively. In addition, a 1008 bp LDLR fragment from c. 18 to c.1026 was amplified. All primers
are listed in S2 Table. The obtained amplicons were purified with ExoSTAR (GEHealthcare)
and sequenced in both 50 and 30 directions in an ABI 3500xl DNA analyzer (Applied
Biosystems).
Statistical analysis
All statistical analyses were performed with SPSS software v.20 (SPSS Inc.). Data are presented
as mean ± standard deviation (SD) for continuous variables, as median and interquartile range
for variables with a skewed distribution, and as frequency for categorical variables. The 51 sub-
jects who took AP were classified according to the detected SNVs in the PCSK9 50 UTR and
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LDLR 30 and 50 UTR regions, and statistical analyses of interindividual variations in LDLc and
total cholesterol were performed. Student’s t-test and Mann-Whitney U test were used as
appropriate. Multivariable linear regression was performed, with LDLc response to AP as the
dependent variable. Those SNVs that showed an association with differences in the LDLc
response to AP were included as independent variables, together with age, sex, basal values of
BMI, cholesterol, LDLc, HDL cholesterol (HDLc), TG, and glucose.
Results
In silico analysis performed with TRANSFAC1, MAPPER, and JASPER revealed that the fol-
lowing SNVs were located in regions that were of interest because of the presence of potential
binding sites for transcription factors: rs2149041 (c.−3383C>G), rs2479406 (c.−2839A>C),
rs17111503 (c.−2063A>G), rs2479408 (c.−1323C>G), and rs2479409 (c.−861A>G) in the
PCSK9 50 UTR, and rs17242346 (c.−2631G>A), rs17248720 (c.−2038C>T), and rs17249120
(c.−729G>A) in the LDLR 50 UTR. By sequencing all fragments that contained these variants
in the study subjects (treated and untreated), we identified a total of 23 variants: 13 in the
PCSK9 50 UTR, three in the LDLR 50 UTR, and seven in the LDLR 30 UTR. The frequencies of
the minor allele ranged from 0.005 to 0.375 (S2 Table). However, to study the effects of genetics
on total and LDL cholesterol response to AP, we considered only the treated subjects in further
analyses.
The LDLc response to AP showed a nonskewed distribution. When subjects were classified
according to their status as carriers of the minor allele of the studied SNVs, statistically signifi-
cant differences (p< 0.05) were observed for c.−3383C>G and c.−2063A>G in the PCSK9 50
UTR and rs14158 (c.52G>A), rs2738465 (c.504G>A), and rs2738466 (c.773A>G) in the
LDLR 30 UTR. For all selected variants, a higher LDLc response to AP was observed for noncar-
riers of the minor alleles (Table 1). Total cholesterol response to AP showed a skewed distribu-
tion, but no statistically significant differences were found when comparing carriers vs
noncarriers of minor alleles in the studied PCSK9 and LDLR SNVs (data not shown).
The effect of c.-3383C>G and c.-2063A>G changes in PCKS9 have been analyzed with
TRANSFAC1, MAPPER, and JASPER and a change in transcription factors pattern has been
observed in both cases. Specifically, the in silico analysis has shown that the presence of the c.-
3383G allele may implicate the abolition of a CD28RC element response.
Table 2 shows the results of multivariable linear regression analysis using the LDLc response
to AP as the dependent variable. Variables that were independently associated with LDLc
response to AP were status as carriers of PCSK9 (c.−3383C>G) and LDLR (c.52G>A) SNVs,
with c.−3383C>G being the more significantly associated of the two variants. Together, these
two minor alleles explained 20.5% of the variability in the LDLc response to AP. PCSK9 c.
−3383C>G accounted for 14.1% of the variability, while the remaining 6.4% was due to LDLR
c.52G>A. Gender, age, and basal clinical data were entered into this model, but no statistical
significance was found.
Fig 1 shows a boxplot of the haplotypes, with the variants c.−3383C>G in PCSK9 and
c.52G>A in LDLR. Subjects were classified as wild type when they did not carry any minor
allele, one-allele carriers, or two-allele carriers, and they were also classified according to their
LDLc response to AP.
Discussion
To the best of our knowledge, the present study was the first to analyze the effect of genetic var-
iants in the 30 UTR of LDLR and the 50 UTR of PCSK9 on response to the hypocholesterolemic
effects of AP treatment. We confirmed that subjects with mild hypercholesterolemia showed a
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different plasma LDLc level response to AP if they were carriers of the common variants
c.52G>A in LDLR and c.−3383C>G in PCSK9.
Several studies have shown that the effects on plasma lipids of changes in dietary interven-
tions differ among individuals, who are consequently classified as hyporesponders or hyper-
responders [21–23]. The fact that extreme responses are reproducible in given individuals sug-
gests that genetic factors may be involved [22, 24]. Treatment with AP was effective at reducing
total cholesterol and LDLc levels in a previous randomized, placebo-controlled, crossover
study of patients with moderate dyslipidemia. However, enormous variability was observed
among individuals in their lipid-lowering response to AP treatment [13]. The mechanisms
underlying the hypolipidemic effects of AP may be based on its main constituents. The lipid-
lowering effects of berberine were first reported in Chinese patients with type IIa or IIb hyper-
lipidemia treated with berberine alone (500 mg twice per day) [17].
A limitation of the present study is that AP is a nutraceutical with several compounds; for
example, red yeast rice extract is similar in structure to lovastatin, and it has been shown to
Table 1. LDL cholesterol response to Armolipid Plus1 in study subjects classified according to be carriers of the minor allele of the PCSK9 and
LDLR Variants.
Gene Variants LDLc response to AP P
Non-carriers Carriers
PCSK9 rs2149041 c.-3383C>G -29.0 ± 15.11 -9.13 ± 28.03 0.008
rs142236283 c.-3365G>A -19.49 ± 23.02 -41.6 0.366
rs79440992 c.-3363A>C -17.76 ± 23.20 -34.10 ± 25.36 0.120
rs140903350 c.-3082delAAGTT -19.75 ± 24.87 -21,50 ± 17,93 0.870
rs2479406 c.-2839A>C -19,96 ± 24,54 -20,20 ± 20,14 0,984
rs2495487 c.-2818A>T -19,56 ± 24,35 -24,25 ± 20.77 0,713
rs2479408 c.-1323C>G -13,80 ± 22,24 -26,29 ± 24,93 0,090
rs41294819 c.-925A>G -17,66 ± 24,17 -29,07 ± 21,55 0.205
rs2479409 c.-861A>G -26,06 ± 16,87 -16,17 ± 26,98 0,184
rs12096557 c.-1072G>A -19,38 ± 24,20 -41,60 0,369
rs17111503 c.-2063A>G -29,4 ± 15,28 -12,15 ± 27,04 0,015
LDLR rs17248720 c.-2038C>T -17,88 ± 28,82 -25,33 ± 16,79 0.383
rs36218923 c.-739A>T -19,90 ± 24,15 -24,00 0,867
rs17239120 c.-729G>A -20,29 ± 24,07 -7.00 0.588
rs17243004 c.*49G>A -20,39 ± 24,35 -7.00 0.590
rs14158 c.*52G>A -25,58 ± 22,39 -10,81 ± 24,85 0,051
rs3826810 c.*141G>A -20,13 ± 24,14 -14,00 0,803
rs2738464 c.*315C>G -21,83 ± 21,72 -10,29 ± 33,49 0,245
rs2738465 c.*504G>A -25,58 ± 22,39 -10,81 ± 24,85 0,051
rs1433099 c.*666A>T -17,52 ± 24,65 -23,03 ± 23,83 0,462
rs2738466 c.*773A>G -25,58 ± 22,39 -10,81 ± 24,85 0,051
LDL colesterol response to Armolipid Plus1 was expressed with mean ± SD. P-value was calculated by T-Student. AP: Armolipid Plus1; LDLc: LDL
colesterol. P: p-value.
doi:10.1371/journal.pone.0150785.t001
Table 2. Genetic variables independently associated with LDLc response to Armpolipid Plus1 by linear regression.
Variables B Standardized Coefficient (β) p-value Added Adjusted R2
PCSK9 c.-3383C>G (no/yes) -17.725 6.717 0.012 0.141
LDLR c.*52G>A (no/yes) -14.050 6.845 0.047 0.205
doi:10.1371/journal.pone.0150785.t002
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have a cholesterol-lowering effect [25]. Although red yeast rice extract is a component of AP,
its concentration compared to that of berberine is low [13]. Another limitation is that we only
considered genetic variations in the 50 and 30 UTR of LDLR and the 50 UTR of PCSK9. Other
genetic variations could also influence the response to AP. Although the effect of the PCSK9
5’UTR SNVs c.-3383C>G and c.-2063A>G have been analyzed and differences in the tran-
scription factors pattern have been observed, the specific effect of those in PCSK9 regulation
and its effect on AP response is not known. It has not been previously shown a relationship
between CD28RC and PCSK9. To confirm our hypothesis further in vitro studies should be
done such as EMSA and luciferase assays, unfortunately we have not been able to perform it
due to budget restrictions.
Our hypothesis in the present study was that differences in the AP hypolipidemic response
are mainly caused by genetic variants that affect the activity of berberine. We observed that
mutations in the LDLR 30 UTR and PCSK9 50 UTR appeared to influence the AP response: car-
riers of c.−3383C>G and c.−2063A>G in PCSK9 and c.52G>A, c.504G>A, and c.773A>G
in LDLR showed a lower response to AP treatment. Moreover, being a carrier of c.−3383C>G
and c.52G>A in PCSK9 and LDLR, respectively, accounted for 20.5% of the variability in the
LDLc response to AP. This may be due to differences in LDLR and PCSK9 post-transcriptional
and transcriptional regulation mediated by berberine.
LDLR expression is regulated at the post-transcriptional level by changes in mRNA stability
[26], which is primarily controlled by regulatory sequences present in the 2.5 kb–long stretch
of the 30 UTR, where three mRNA destabilizing elements, called AU-rich elements (AREs),
Fig 1. Study subjects classified according to status as carriers of c.−3383C>G PCSK9 and c.*52G>A LDLR variants and response of LDL
cholesterol levels to Armolipid Plus.
doi:10.1371/journal.pone.0150785.g001
Genetic Variants and Armolipid Plus Response
PLOS ONE | DOI:10.1371/journal.pone.0150785 March 25, 2016 6 / 9
have been identified as responsible for the rapid turnover rate of LDLR mRNA. Previous inves-
tigations of these SNPs showed no differences in the allele distribution within subjects with or
without coronary heart disease [26]. However, the effect of these variants on the response to
AP, particularly berberine, has not been previously analyzed. We found a difference in the AP
response in subjects who were carriers of c.52G>A, c.504G>A, and c.773A>G. Variants
c.52G>A and c.773A>G are located around the first and third AREs, respectively, and they
are in linkage disequilibrium [27]. Only the c.52G>A variant was included in the regression
model, and it explained 6.4% of the response variability to AP. Recently, it was shown to have
an effect on hnRNP D in the regulation of LDLR mRNA stability in berberine-treated mice
[28].
Recently, berberine was also identified in HepG2 cells as a regulator of PCSK9 transcrip-
tional activity by inducing HNF1α via the ubiquitin proteasome system [29]. HNF1α is the
principal form of HNF1 factors, and it stimulates PCSK9 transcription. Whereas statins induce
PCSK9 transcription by enhancing the binding of SREBP2 to SRE-1, berberine decreases the
cellular abundance of HNF1α and SREBP2, which results in reduced interaction of these two
critical transactivators with their recognition sequences in the PCSK9 promoter and leads to
transcriptional repression. Carriers of minor alleles c.−3383C>G and c.−2063A>G, which are
in the PCSK9 50 UTR, showed a lower response to AP treatment. Moreover, the c.−3383C>G
variant alone was responsible for 14.1% of the variability in the response to AP treatment.
Moreover, we observed that being a carrier of one or two of the minor alleles LDLR c.52G>A
and PCSK9 c.−3383C>G was associated with a lower response to AP.
In summary, three polymorphism in the LDLR 30 UTR, c.52G> A, c.504 G>A, and
c.773A>G, and two in the PCSK9 50 UTR, c.−3383C>G and c.−2063A>G, were associated
with response to AP. The c.52G>A LDLR variant, together with c.−3383C>G of PCSK9,
could explain 20.5% of the variation in therapeutic response; carriers of one or more of these
variants were more hyporesponsive to AP compared to those who were not carriers. These
results could explain the differences in the response to berberine, and they suggest that analysis
of these variants in individuals could be useful in providing people with personalized nutrition
advice. Finally, based on our results and those of previous studies, we hypothesize that berber-
ine has dual actions on LDLR metabolism, by prolonging the LDLRmRNA half-life as well as
by directly increasing LDLR protein abundance through the blockage of PCSK9-mediated deg-
radation. Thus, berberine and berberine-like compounds may be attractive therapeutic candi-
dates for enhancing statin efficacy and should be investigated further in randomized clinical
trials.
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